Registered outcomes29

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

21 to 29 of 29

List	Outcome	Time frame	Description
Secondary	Duration of hospitalizations	Up to Week 24
Secondary	Plasma concentration of unchanged ASP1517	Up to Week 24
Secondary	Safety assessed by incidence of adverse events	Up to Week 24
Secondary	Number of participants with abnormal Laboratory values and/or adverse events related to treatment	Up to Week 24
Secondary	Number of participants with abnormal Vital signs and/or adverse events related to treatment	Up to Week 24
Secondary	Number of participants with abnormal 12-lead electrocardiogram (ECG) values	Up to Week 24	Any clinically significant adverse changes on the ECG will be reported as adverse events.
Secondary	Safety assessed by ophthalmological examination: fundoscopy	Up to Week 24
Secondary	Safety assessed by ophthalmological examination: Optical coherence tomography	Up to Week 24
Secondary	Safety assessed by ophthalmological examination: visual acuity	Up to Week 24

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02952092/registered?page=2